Moderna raised its 2026 revenue-growth forecast to 15%–25%, up from its previous outlook of growth of up to 10%.
Third-quarter revenue rose 29% year over year to about $1.31 billion, driven mainly by stronger COVID-19 vaccine sales overseas and deliveries under government partnerships.
The company is expanding beyond COVID vaccines:
its newer mNEXSPIKE vaccine is contributing, while its recently approved mFLUSIVA flu vaccine is expected to have a limited U.S. launch in 2026.
Moderna also pointed to positive late-stage results for its experimental personalized melanoma vaccine, developed with Merck, as part of its longer-term growth pipeline.
The updated outlook is encouraging, but current sales growth is still largely tied to COVID vaccine demand; newer products are only beginning to contribute.
Sources:
Moderna (MRNA) earnings Q3 2026
Moderna Lifts Outlook, Swings to 3Q Profit - Morningstar
Moderna lifts annual revenue forecast on strong COVID vaccine demand ...
Moderna lifts annual revenue forecast on strong COVID ...
What Moderna (MRNA) Said on Its Q3 Earnings Call
Moderna shares surge 10% on earnings beat and raised revenue outlook
sec-gov-archives-edgar-data-1682852-000168285226000194-exhibit9912026q3pressrelea-htm
Moderna lifts revenue outlook after return to profit
Moderna Shares Jump 10% as Q3 Earnings Beat Forecasts and Revenue Outlook Improves
Moderna Returns To Q3 Profit; Raises FY26 Outlook On Vaccine Sales And Pipeline Progress
Moderna Delivers Surprise Profit, Raises 2026 Outlook
Moderna bumps up growth outlook as newer vaccines ...
Moderna Stock Soars After $162 Million Profit Reverses Last Year's Loss